Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms.

Who benefits? The reduced price applies to self-paying patients—those without insurance, or whose insurance doesn’t cover Ozempic. More than 70,000 U.S. pharmacies are participating through partnerships with GoodRx and NovoCare, Novo Nordisk’s cash-pay pharmacy.

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy (semaglutide) available to eligible self-paying patients for $499 per month.